Nitrosamine Impurities Testing

Introduction:

Nitrosamine Impurities Testing is the analytical process used to detect and quantify nitrosamine compounds—potentially carcinogenic impurities—in pharmaceutical products and active pharmaceutical ingredients (APIs).

Nitrosamines gained global attention after their detection in several marketed drugs, prompting strict regulatory oversight. Today, manufacturers must perform risk assessments and confirmatory testing to ensure patient safety and regulatory compliance.

At ResolveMass Laboratories Inc., we specialize in ultra-trace analysis of nitrosamines using advanced LC-MS/MS and GC-MS technologies aligned with international regulatory expectations.

Summary:

Nitrosamine Impurities Testing is essential to detect and quantify carcinogenic nitrosamines in APIs and drug products.
Global regulators including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada require risk assessment and confirmatory testing.
Highly sensitive LC-MS/MS and GC-MS/MS methods are needed to detect nitrosamines at ng/g (ppb) levels.
Testing involves risk assessment, method development, validation, and regulatory documentation.
ResolveMass Laboratories Inc. provides expert, compliance-driven nitrosamine testing solutions with advanced mass spectrometry platforms.

1: Why Is Nitrosamine Impurities Testing Required?

Nitrosamine Impurities Testing is required because nitrosamines are classified as probable human carcinogens and must be controlled at extremely low limits.

Regulatory bodies worldwide have issued guidance requiring manufacturers to:

Conduct risk assessments for APIs and finished products
Perform confirmatory testing where risk is identified
Establish acceptable intake (AI) limits
Implement mitigation strategies

Key Regulatory Authorities

U.S. Food and Drug Administration
European Medicines Agency
Health Canada

These agencies mandate compliance with strict permissible daily intake limits—often in the nanogram range.

Read about AI Integration in Nitrosamine Testing for Efficiency

2: What Are Nitrosamines?

Nitrosamines are chemical compounds formed by the reaction of secondary or tertiary amines with nitrosating agents.

They can form during:

API synthesis
Recovered solvent reuse
Storage conditions
Packaging interactions
Degradation processes

Common Nitrosamines Detected in Pharmaceuticals

Nitrosamine	Full Name	Commonly Associated With
NDMA	N-Nitrosodimethylamine	Solvent reuse, amine contamination
NDEA	N-Nitrosodiethylamine	Amine-containing APIs
NMBA	N-Nitroso-N-methyl-4-aminobutyric acid	ARB drugs
DIPNA	N-Nitrosodiisopropylamine	Manufacturing impurities
EIPNA	N-Nitrosoethylisopropylamine	Synthetic process risks

Because acceptable intake limits are extremely low (often < 100 ng/day), highly sensitive instrumentation is required.

Also explore: Comprehensive Nitrosamine Analysis Laboratory Services: What Pharmaceutical Companies Need to Know

3: How Is Nitrosamine Impurities Testing Performed?

Nitrosamine Impurities Testing is performed using highly sensitive mass spectrometry techniques such as LC-MS/MS and GC-MS/MS capable of detecting trace-level impurities.

Step 1: Risk Assessment

Manufacturers evaluate:

Raw materials
Synthetic route
Reagents and catalysts
Solvent recovery practices
Packaging interactions

Step 2: Method Development

ResolveMass develops compound-specific methods using:

LC-MS/MS for polar nitrosamines
GC-MS/MS for volatile nitrosamines
Isotope-labeled internal standards
Matrix-specific extraction techniques

Step 3: Method Validation

Validation typically includes:

Specificity
Accuracy and precision
Linearity
Limit of Detection (LOD)
Limit of Quantification (LOQ)
Robustness

Step 4: Routine Testing & Regulatory Documentation

Results are compiled into:

Analytical reports
Validation protocols
Risk mitigation documentation
Regulatory submission support

How Is Nitrosamine Impurities Testing Performed?

Explore our Nitrosamine Testing Services in Canada and the US

4: Nitrosamine Impurities Testing Regulatory Limits

Regulatory agencies set acceptable intake limits for nitrosamines based on carcinogenic risk assessment models.

Limits vary depending on:

Type of nitrosamine
Maximum daily dose of drug
Treatment duration

Example Acceptable Intake (AI) Limits

Nitrosamine	Approximate AI Limit (ng/day)
NDMA	96 ng/day
NDEA	26.5 ng/day
NMBA	96 ng/day

Manufacturers must ensure total nitrosamine levels remain below these limits throughout product shelf life.

Learn more about how to Avoid United States FDA Recalls with Routine Nitrosamine Impurity Testing for Your API and Drug Product

5: Challenges in Nitrosamine Impurities Testing

Nitrosamine Impurities Testing is technically challenging due to ultra-low detection requirements and matrix complexity.

Key Challenges

Detection at ppb or ppt levels
Matrix interference from complex formulations
Cross-contamination risks
Artifact formation during analysis
Instrument sensitivity and stability

ResolveMass addresses these challenges using:

High-resolution triple quadrupole mass spectrometers
Dedicated nitrosamine workflows
Stringent contamination control protocols
Experienced analytical chemists

Challenges in Nitrosamine Impurities Testing

6: Case Study: Nitrosamine Impurities Testing for a Pharmaceutical Clients

A leading pharmaceutical company approached Resolvemass Laboratories for nitrosamine testing services for one of their drug products. The company needed to ensure compliance with the latest regulatory guidelines on nitrosamine impurities. Here’s how we addressed their needs:

Challenges

Complex Matrix: The drug product had a complex formulation, making the extraction and analysis of nitrosamines challenging.
Low Detection Limits: The required detection limits for nitrosamines were in the parts-per-billion (ppb) range, necessitating highly sensitive and specific analytical methods. If you want to know more about limits of Nitrosamine Impurities, you can read this article: Nitrosamine Impurity Limits and Acceptable Intake for Health Canada: How to Stay Compliant
Regulatory Compliance: The company needed to comply with stringent regulatory guidelines from both the FDA and EMA.

Solution

Optimized Sample Preparation: We developed a customized sample preparation method to effectively extract nitrosamines from the complex matrix. This involved using a combination of SPE and LLE techniques to achieve high recovery rates.
Advanced Chromatography and MS Techniques: Our team employed high-resolution GC-MS/MS to achieve the required sensitivity and specificity for detecting nitrosamines at trace levels. The method was validated to ensure it met all regulatory requirements.
Comprehensive Reporting and Guidance: We provided the client with detailed reports on the levels of nitrosamine impurities detected, along with expert guidance on regulatory compliance and recommendations for mitigating the presence of nitrosamines in their product.

Outcome

The successful detection and quantification of nitrosamine impurities enabled the pharmaceutical company to comply with regulatory guidelines and ensure the safety of their drug product. Our comprehensive testing and expert guidance helped them address potential risks and implement corrective measures in their manufacturing process.

7: Nitrosamine Impurities Testing for APIs vs Finished Products

Nitrosamine Impurities Testing differs for APIs and finished dosage forms due to matrix differences and formulation complexity.

API Testing

Focus on process-related impurities
Higher control over matrix
Evaluation of synthetic route risk

Finished Product Testing

Tablet, capsule, injectable matrix interference
Stability-related formation assessment
Packaging interaction studies

ResolveMass customizes testing strategies based on product type and regulatory pathway (ANDA, NDA, DMF, etc.).

8: When Should You Perform Nitrosamine Impurities Testing?

Nitrosamine Impurities Testing should be performed during development, before regulatory submission, and as part of lifecycle management.

Recommended Stages

Early development risk assessment
Pre-ANDA / NDA submission
Post-approval changes
Supplier change
Process modification
Stability studies

Proactive testing prevents regulatory delays, warning letters, and costly recalls.

9: How ResolveMass Laboratories Ensures Reliable Nitrosamine Impurities Testing

At ResolveMass Laboratories Inc., our approach is built on scientific rigor, regulatory understanding, and advanced analytical expertise.

Our Capabilities

State-of-the-art LC-MS/MS & GC-MS/MS platforms
Ultra-trace quantification at ng/g levels
Method development & full validation
Regulatory-compliant documentation
Experienced mass spectrometry scientists
Dedicated nitrosamine contamination control procedures

Why Clients Trust ResolveMass

Proven expertise in complex impurity analysis
Deep regulatory knowledge
Transparent communication
Fast turnaround times
Data integrity and compliance focus

Our laboratory operates under strict quality systems to ensure reproducibility, accuracy, and defensible regulatory submissions.

Conclusion:

Nitrosamine Impurities Testing is no longer optional—it is a regulatory and patient safety necessity.

With global scrutiny from authorities like the FDA, EMA, and Health Canada, pharmaceutical manufacturers must ensure rigorous risk assessment, ultra-trace detection, and comprehensive documentation.

ResolveMass Laboratories Inc. combines advanced mass spectrometry capabilities with deep regulatory expertise to deliver reliable, compliant, and defensible nitrosamine testing solutions.

If you are developing APIs or finished drug products, proactive Nitrosamine Impurities Testing can protect your submission timelines, brand reputation, and most importantly, patient safety.

Also, we tried to cover many FAQs on Nitrosmine testing in this article: Your Nitrosamine Impurity Testing FAQ: Answers for Regulatory Readiness and Confirmatory Analysis

Contact Us

For more information about our mass spectrometry testing services and how we can assist with nitrosamine impurities testing, please visit Resolvemass laboratories & contact us

Frequently Asked Questions:

1. What are nitrosamines and why are they a concern in pharmaceuticals?

Nitrosamines are a class of carcinogenic compounds formed by the reaction of nitrites and secondary or tertiary amines. They are of concern in pharmaceuticals due to their potential presence as impurities, especially in APIs and drug formulations. Regulatory agencies now require stringent risk assessments and confirmatory testing to ensure patient safety.

2. Which regulatory guidelines govern nitrosamine impurity testing?

Key guidelines include the FDA’s “Control of Nitrosamine Impurities in Human Drugs,” EMA’s Q&A on nitrosamines, Health Canada’s nitrosamine guidance, and ICH M7(R1) for mutagenic impurities. These documents outline acceptable intake limits (AIs), risk assessment procedures, and analytical validation requirements.

3. What is the Acceptable Intake (AI) limit for NDMA in drug products?

The AI limit for NDMA (N-nitrosodimethylamine) is typically 96 ng/day, as defined by the FDA and EMA. This threshold may vary slightly depending on jurisdiction and duration of exposure, but exceeding it requires immediate regulatory action.

4. What are the most commonly detected nitrosamines in drugs?

Common nitrosamines include:
-NDMA (N-Nitrosodimethylamine)
-NDEA (N-Nitrosodiethylamine)
-NMBA (N-Nitroso-N-methyl-4-aminobutyric acid)
-NEIPA, NDIPA, NDBA, and NDSRIs (Drug Substance-Related Impurities)

5. How are nitrosamines detected in pharmaceutical samples?

Detection is typically performed using highly sensitive and selective methods such as:
-LC-MS/MS (Liquid Chromatography–Mass Spectrometry)
-GC-MS (Gas Chromatography–Mass Spectrometry)
-HRMS (High-Resolution Mass Spectrometry)
These platforms allow quantification down to parts-per-billion (ppb) levels.

6. What is the process for nitrosamine risk assessment in drug development?

Risk assessment involves:
-Evaluating the synthesis pathway and raw materials for nitrosating agents and secondary amines.
-Estimating potential nitrosamine formation.
-Testing at-risk products.
Implementing control strategies if nitrosamines are present.

7. How does ResolveMass Laboratories perform nitrosamine confirmatory testing?

ResolveMass uses validated LC-MS/MS and GC-MS/MS methods per ICH Q2 guidelines. Confirmatory testing includes method-specific quantification, matrix interference evaluation, and LOQ/LOD determination. Full regulatory submission support is provided with comprehensive data packages.

8. What is the detection limit for nitrosamines using LC-MS/MS?

Detection limits typically range from 0.03–0.1 ppb depending on the compound and matrix. LC-MS/MS methods at ResolveMass are optimized to detect nitrosamines well below regulatory thresholds.

9. Can nitrosamine impurities form during storage?

Yes. Some nitrosamines can form during storage due to degradation of excipients or interaction with packaging materials. Stability studies are essential to evaluate nitrosamine formation over time.

10. What are NDSRIs and how are they different from typical nitrosamines?

NDSRIs (Nitrosamine Drug Substance-Related Impurities) are nitrosamines structurally related to the API. Unlike common nitrosamines, they are compound-specific and harder to predict, often requiring custom synthesis of reference standards and tailored analytical methods.

11. How are NDSRI impurities synthesized for analysis?

At ResolveMass, NDSRIs are synthesized using controlled reactions between known API precursors and nitrosating agents. These standards are then purified and characterized using NMR, LC-MS, and HPLC to confirm identity and purity.

12. What is the role of forced degradation studies in nitrosamine testing?

Forced degradation under acidic, basic, thermal, and oxidative conditions helps assess nitrosamine formation potential. These studies guide formulation changes and storage recommendations to minimize impurity risks.

13. How long does nitrosamine method development typically take?

Depending on matrix complexity and regulatory requirements, method development at ResolveMass typically takes 5–10 business days for standard nitrosamines, and up to 20 days for custom NDSRIs.

14. What is the importance of method validation in nitrosamine analysis?

Method validation ensures accuracy, precision, specificity, and sensitivity. It is required for regulatory compliance and essential for building trust in analytical results used in NDA/ANDA submissions.

15. Can nitrosamine testing be expedited for regulatory filings?

Yes. ResolveMass offers expedited services with priority method development, real-time communication, and rapid reporting to support tight NDA/ANDA timelines.

Reference

Analytical Methodologies to Detect N-Nitrosamine Impurities in Active Pharmaceutical Ingredients, Drug Products and Other Matrices.https://pubs.acs.org/doi/full/10.1021/acs.chemrestox.4c00234
Yunes M. M. A. Alsayadi ,Raghav Dogra. Innovations in the Detection of N-Nitrosamine Impurities in Pharmaceuticals: Analytical and Regulatory Challenges.https://www.tandfonline.com/doi/abs/10.1080/10408347.2025.2512443
An update on latest regulatory guidelines and analytical methodologies for N-nitrosamine impurities in pharmaceutical products – 2024.https://journals.lww.com/mgar/fulltext/2025/12000/an_update_on_latest_regulatory_guidelines_and.10.aspx
Nitrosamine Impurities in Drug Substances and Drug Products.https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3958595
Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.0c02120

Nitrosamine Risk in Solid vs Liquid Dosage

ResolveMass Laboratories

Introduction:

Summary: